logo-loader
viewANGLE PLC

ANGLE to offer a full liquid biopsy 'sample to answer' solution following Axela acquisition

Andrew Newland, chief executive of ANGLE PLC (LON:AGL) (OTCQX:ANPCY) managed to find a quiet corner at Gatwick Airport, just minutes before flying out to Europe's leading CTC conference in Rhodes, to discuss their decision to acquire some assets from a Canadian company with intellectual property that complements ANGLE’s Parsortix liquid biopsy platform.

ANGLE is paying C$6.16mln, or roughly £3.7mln, for the assets.

Eight of the Axela team will be moving on to ANGLE’s payroll.

The Axela system will complement Parsortix by providing an analysis element to ANGLE’s offering, enabling the UK company to capture a greater proportion of the liquid biopsy value chain.

Quick facts: ANGLE PLC

Price: 77 GBX

AIM:AGL
Market: AIM
Market Cap: £133.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read